305,233 Shares in Kenvue Inc. $KVUE Purchased by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp acquired a new position in shares of Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 305,233 shares of the company’s stock, valued at approximately $5,833,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Physician Wealth Advisors Inc. lifted its stake in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the last quarter. Elyxium Wealth LLC bought a new position in shares of Kenvue during the 4th quarter valued at approximately $26,000. Johnson Financial Group Inc. purchased a new stake in Kenvue during the 2nd quarter valued at $26,000. MV Capital Management Inc. purchased a new stake in Kenvue during the 4th quarter valued at $28,000. Finally, CoreCap Advisors LLC raised its holdings in Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after buying an additional 591 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on KVUE. Barclays lifted their price objective on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. UBS Group lowered their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Wall Street Zen downgraded shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Three equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $19.27.

Kenvue Price Performance

Shares of KVUE stock opened at $19.41 on Tuesday. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $21.63. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. The firm has a market capitalization of $37.27 billion, a P/E ratio of 22.30, a P/E/G ratio of 1.36 and a beta of 0.47. The stock has a 50 day moving average price of $19.08 and a 200 day moving average price of $18.21.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). The business had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business’s revenue was up 3.0% compared to the same quarter last year. During the same period last year, the company earned $0.29 EPS. As a group, sell-side analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be paid a dividend of $0.21 per share. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date of this dividend is Wednesday, August 12th. Kenvue’s payout ratio is presently 96.55%.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.